TY  - JOUR
A1  - Wiegering, Verena
A1  - Andres, Oliver
A1  - Schlegel, Paul G.
A1  - Deinlein, Frank
A1  - Eyrich, Matthias
A1  - Sturm, Alexander
T1  - Hyperfibrinolysis and acquired factor XIII deficiency in newly diagnosed pediatric malignancies
JF  - Haematologica
N2  - No abstract available
KW  - factor XIII deficiency
KW  - leukemia
KW  - tumor
KW  - perioperative bleeding
KW  - coagulopathy
KW  - hyperfibrinolysis
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130569
VL  - 98
IS  - 8
ER  - 
TY  - JOUR
A1  - Wiegering, Verena
A1  - Schmid, Sophie
A1  - Andres, Oliver
A1  - Wirth, Clemens
A1  - Wiegering, Armin
A1  - Meyer, Thomas
A1  - Winkler, Beate
A1  - Schlegel, Paul G.
A1  - Eyrich, Matthias
T1  - Thrombosis as a complication of central venous access in pediatric patients with malignancies: a 5-year single-center experience
N2  - Background

Reliable central venous access (CVC) is essential for hematology–oncology patients since frequent puncture of peripheral veins—e.g., for chemotherapy, antibiotic administration, repeated blood sampling, and monitoring—can cause unacceptable pain and psychological trauma, as well as severe side effects in cases of extravasation of chemotherapy drugs. However, CVC lines still carry major risk factors, including thrombosis, infection (e.g., entry site, tunnel, and luminal infections), and catheter dislocation, leakage, or breakage.

Methods

Here we performed a retrospective database analysis to determine the incidence of CVC-associated thrombosis in a single-center cohort of 448 pediatric oncologic patients, and to analyze whether any subgroup of patients was at increased risk and thus might benefit from prophylactic anticoagulation.

Results

Of the 448 patients, 269 consecutive patients received a CVC, and 55 of these 269 patients (20%) also had a thrombosis. Of these 55 patients, 43 had at least one CVC-associated thrombosis (total number of CVC-associated thrombosis: n = 52). Among all patients, the median duration of CVC exposure was 464 days. Regarding exposure time, no significant difference was found between patients with and without CVC-associated thrombosis. Subclavia catheters and advanced tumor stages seem to be the main risk factors for the development of CVC-associated thrombosis, whereas pharmacologic prophylaxis did not seem to have a relevant impact on the rate of thrombosis.

Conclusions

We conclude that pediatric surgeons and oncologists should pay close attention to ensuring optimal and accurate CVC placement, as this appears the most effective tool to minimize CVC-associated complications.
KW  - Pediatric malignancy
KW  - Central venous access
KW  - Port
KW  - Hickman catheter
KW  - Thrombosis
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-110476
ER  - 
TY  - JOUR
A1  - Krakow, Sören
A1  - Crescimone, Marie L.
A1  - Bartels, Charlotte
A1  - Wiegering, Verena
A1  - Eyrich, Matthias
A1  - Schlegel, Paul G.
A1  - Wölfl, Matthias
T1  - Re-expression of CD14 in response to a combined IL-10/TLR stimulus defines monocyte-derived cells with an immunoregulatory phenotype
JF  - Frontiers in Immunology
N2  - Interleukin 10 is a central regulator of the antigen-presenting function of myeloid cells. It exerts immunomodulatory effects in vivo and induces a regulatory phenotype in monocyte-derived cells in vitro. We analyzed phenotype and function of monocytic cells in vitro in relation to the cytokine milieu and the timing of TLR-based activation. In GM-CSF/IL-4 cultured human monocytic cells, we identified two, mutually exclusive cell populations arising from undifferentiated cells: CD83\(^+\) fully activated dendritic cells and CD14\(^+\) macrophage like cells. Re-expression of CD14 occurs primarily after a sequential trigger with a TLR signal following IL-10 preincubation. This cell population with re-expressed CD14 greatly differs in phenotype and function from the CD83+ cells. Detailed analysis of individual subpopulations reveals that exogenous IL-10 is critical for inducing the shift toward the CD14\(^+\) population, but does not affect individual changes in marker expression or cell function in most cases. Thus, plasticity of CD14 expression, defining a subset of immunoregulatory cells, is highly relevant for the composition of cellular products (such as DC vaccines) as it affects the function of the total product.
KW  - regulatory dendritic cells
KW  - MDSC
KW  - monocyte-derived DC
KW  - IL-10
KW  - macrophages
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-201537
VL  - 10
IS  - 1484
ER  -